Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa

ConditionsPseudomonas Infections Pseudomonas Aeruginosa Prognosis Drug Resistance, Multiple, Bacterial Antibacterial Agents Beta-lactam Antibiotics

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorCentre Hospitalier Régional d'Orléans

About this trial

The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam/beta-lactamase inhibitor combination, cefiderocol or older agents such as aminoglycosides and colistin) in unselected patients with infection due to difficult-to-treat P. aeruginosa.

Eligibility criteria

Qualifiers

All patients aged 18 or over and requiring intravenous definite antimicrobial therapy for a DTR P. aeruginosa infection

Disqualifiers

Cystic fibrosis

P. aeruginosa DTR colonization or P. aeruginosa DTR infection not requiring definitive intravenous antibiotic therapy

Protected person (under guardianship or curatorship)

Persons under court protection

Trial design

Treatments tested in this trial

Not listed

Trial groups

600 Participants

are grouped into 1 trial group

Locations48

Select a site below to view it on the map.

France

Reunion

Sponsors and collaborators

Centre Hospitalier Régional d'Orléans

Lead sponsor

Source ClinicalTrials.gov